Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Shaanxi Meibang Pharmaceutical Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 7.10%.
SHSE:605033'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.35 Med: 40.14 Max: 52.99
Current: 9.37
During the past 9 years, Shaanxi Meibang Pharmaceutical Group Co's highest ROC (Joel Greenblatt) % was 52.99%. The lowest was 6.35%. And the median was 40.14%.
SHSE:605033's ROC (Joel Greenblatt) % is ranked worse than 53.88% of 258
companies
in the Agriculture industry
Industry Median: 10.575
vs SHSE:605033: 9.37
Shaanxi Meibang Pharmaceutical Group Co (SHSE:605033) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shaanxi Meibang Pharmaceutical Group Co ROC (Joel Greenblatt) % Chart
Shaanxi Meibang Pharmaceutical Group Co Annual Data
SHSE:605033 vs CTVA, CF, MOS: ROC (Joel Greenblatt) % Comparison
For the Agricultural Inputs subindustry, Shaanxi Meibang Pharmaceutical Group Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shaanxi Meibang Pharmaceutical Group Co ROC (Joel Greenblatt) % vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Shaanxi Meibang Pharmaceutical Group Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Shaanxi Meibang Pharmaceutical Group Co's ROC (Joel Greenblatt) % falls into.
Shaanxi Meibang Pharmaceutical Group Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 7.10% mean?
Shaanxi Meibang Pharmaceutical Group Co (SHSE:605033) has a ROC (Joel Greenblatt) % of 7.10% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Shaanxi Meibang Pharmaceutical Group Co and its competitors. This is 82% below median its historical median of 40.14. Over the past decade, Shaanxi Meibang Pharmaceutical Group Co's ROC (Joel Greenblatt) % has ranged from 6.35 to 52.99. According to the industry distribution chart, Shaanxi Meibang Pharmaceutical Group Co ranks #139 out of 258 companies in the Agriculture industry, placing it in the top 53.9%.
Is Shaanxi Meibang Pharmaceutical Group Co's ROC (Joel Greenblatt) % too high?
Shaanxi Meibang Pharmaceutical Group Co's current ROC (Joel Greenblatt) % of 7.10% is 82% below median its 10-year median of 40.14. Over the past 10 years, this metric has ranged from a low of 6.35 to a high of 52.99. The Agriculture industry median ROC (Joel Greenblatt) % is 10.58. Shaanxi Meibang Pharmaceutical Group Co's value of 7.10% is 32.9% below this industry median. Based on the distribution chart, Shaanxi Meibang Pharmaceutical Group Co ranks #139 out of 258 companies in the Agriculture industry, which is below the industry midpoint. Overall, Shaanxi Meibang Pharmaceutical Group Co has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shaanxi Meibang Pharmaceutical Group Co's ROC (Joel Greenblatt) % compare to CTVA and CF?
According to the Agriculture industry distribution chart, Shaanxi Meibang Pharmaceutical Group Co ranks #139 out of 258 companies for ROC (Joel Greenblatt) %. This places Shaanxi Meibang Pharmaceutical Group Co in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 10.58. Shaanxi Meibang Pharmaceutical Group Co's value of 7.10% is 32.9% below this benchmark. Historically, Shaanxi Meibang Pharmaceutical Group Co's own ROC (Joel Greenblatt) % has ranged from 6.35 to 52.99 over the past decade. While the company's 10-year median is 40.14 vs. the industry median of 10.58, Shaanxi Meibang Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for an Agriculture company?
The median ROC (Joel Greenblatt) % among Agriculture companies is 10.58, based on 258 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shaanxi Meibang Pharmaceutical Group Co's current ROC (Joel Greenblatt) % of 7.10% is 32.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Shaanxi Meibang Pharmaceutical Group Co and its competitors. For the Agriculture industry, the median ROC (Joel Greenblatt) % is 10.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shaanxi Meibang Pharmaceutical Group Co's current ROC (Joel Greenblatt) % is 7.10%, which is 82% below median its own 10-year median of 40.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shaanxi Meibang Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Shaanxi Meibang Pharmaceutical Group Co (SHSE:605033) is currently considered Fairly Valued. The stock's GF Value™ is ¥22.04, compared to a current price of ¥20.30 — trading 7.9% below its estimated fair value. The current ROC (Joel Greenblatt) % is 7.10%, which is 82% below median its 10-year median of 40.14 and 32.9% below the Agriculture industry median of 10.58. Shaanxi Meibang Pharmaceutical Group Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Shaanxi Meibang Pharmaceutical Group Co (SHSE:605033), the current ROC (Joel Greenblatt) % is 7.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shaanxi Meibang Pharmaceutical Group Co (SHSE:605033) Overvalued in 2026?
Based on GuruFocus' analysis, Shaanxi Meibang Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥20.30 is trading 7.9% below its estimated GF Value™ of ¥22.04.
GuruFocus considers Shaanxi Meibang Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:605033:
ROC (Joel Greenblatt) %: 7.10% (82% below median its 10-year median of 40.14)
GF Value™: ¥22.04 vs. price of ¥20.30 (7.9% below fair value)
Industry Position: 32.9% below the Agriculture median (#139 of 258)
No single metric tells the full story. See the SHSE:605033 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605033 has been successfully added to your 
